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A Single Center and Paired Kidney Analysis of Tacrolimus and Neoral-
based Therapy in Chinese Cadaveric Renal Transplant Recipients
CY Cheung, F Wong, HW Chan, YL Liu, YH Chan, HS Wong, WL Chak,
KS Choi, KF Chau, CS Li
Renal Unit, Department of Medicine, Queen Elizabeth Hospital, Kowloon, Hong
Kong SAR, China.
Background: Tacrolimus has been shown to be superior to cyclosporine in the
prevention of acute rejection in several randomized studies. However, few of
these studies used paired kidneys for analysis. Moreover, most of the published
data used whole blood trough levels for drug monitoring. Different studies
have shown that the use of limited sampling strategy and abbreviated formula
to estimate the 12-hour area under the concentration-time curve (AUC0–12)
allowed better prediction of drug exposure. Methods: A total of 66 Chinese
first cadaveric renal transplant recipients received paired kidneys between 1st
June 1998 and 31st December 2004. They were randomized to receive either
tacrolimus-based (n = 33) or cyclosporine/Neoral-based therapies (n = 33).
Abbreviated AUC0-12 was used for drug monitoring and dose titration. The mean
follow-up duration was 2.3 ( 2.2 years. Results: Patient and graft survival
were comparable. A lower incidence of acute rejection was observed in the
tacrolimus group (15% vs 27.3%), although the difference was insignificant
(p = 0.23). The creatinine clearance was significantly better in tacrolimus-treated
patients beginning from 6 months until 5 years after transplantation. The
prevalence of hypertension, post-transplant diabetes mellitus, infection and
malignancy were similar in both groups. The prevalence of hypercholesterolemia
(11/33 vs 4/33) and gum hypertrophy (6/33 vs 1/33) was higher in Neoral-
treated patients (p = 0.04 for both). Conclusion: Renal function was significantly
better in the tacrolimus group in this paired kidney analysis. The use of
abbreviated AUC0–12 provided a better tool for drug monitoring than traditional
trough level measurement.
Glomerular Pathology of Allograft Kidneys
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Background: To review glomerular diseases diagnosed in allograft kidneys
and to correlate them with clinical parameters. Methods: Eight hundred and
ninety-one renal graft biopsies and 43 graft nephrectomies filed in Queen Mary
Hospital from 1980 to 2004 were studied. They came from 442 allografts
transplanted to 425 patients. Results: Glomerular diseases were diagnosed in
33.0% of kidney grafts. Indications for biopsy were baseline assessment
(23 biopsies, 2.5%), renal dysfunction (790 biopsies, 88.7%), proteinuria (154
biopsies, 17.3%), hematuria (11 biopsies, 1.2%), and by protocol (4 biopsies,
0.4%). The median time post-transplant when the biopsies were procured was
less than 8 months. The mean time post-transplant for diagnosing IgA
nephropathy (IgAN), transplant glomerulopathy (TG), focal segmental
glomerulosclerosis (FSG), mesangiocapillary glomerulonephritis (MCGN),
membranous GN, mesangial proliferative GN, and diabetic nephropathy was
70, 66, 65, 55, 45, 49, and 101 months, respectively. Specific glomerular diseases
were diagnosed by biopsies in 106 of 119 (89.1%) proteinuric allografts.
Recurrent glomerular disease was documented in 31 (7.0%) grafts. Conclusion:
Glomerulopathy was common in allograft biopsies. IgAN, TG, FSG, mesangial
proliferative GN, and membranous GN comprised the majority. A higher
proportion of grafts from donors related to the recipients than from unrelated
donors had IgAN (p < 0.05), and there was no difference in the time to diagnose
IgAN post-transplant between the two groups, suggesting that genetic factors
might play a role in its pathogenesis. Recurrence of glomerulopathy underlying
end-stage renal disease was frequent for IgAN, FSG, and MCGN, but this was
rare for membranous GN.
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Background and Methods: In order to understand the clinical outcome of
HCV-infected renal allograft recipients, a retrospective review was conducted
in July 2005 to study the clinical course of renal allograft recipients followed-
up in the renal unit of Princess Margaret Hospital since January 2002. Results:
In 2002, 23 out of 404 renal transplant recipients were HCV-infected. The male:
female ratio was 12:11; 82.6% of HCV-infected patients had cadaveric renal
transplantation in China; 69.6% of HCV-infected patients were HCV-RNA
positive. The predominant HCV genotype was 1b (56.3%). Other genotypes
were: 1a, 18.8%; 2a, 12.5%; 3b, 6.2%; and 6a, 6.2%. Only two patients had co-
hepatitis B virus infection. Two patients had liver biopsy before transplantation;
both showed features of chronic hepatitis but they had stable graft and liver
functions. None of them had acute flare up of hepatitis or hepatocellular
carcinoma. One patient developed liver cirrhosis, while two eventually resumed
dialysis due to graft failure. The mortality rates of HCV-infected and non-HCV-
infected renal allograft recipients were 17.4% and 1.6%, respectively. Four
HCV-infected recipients died: two died of severe sepsis with multiple organ
failure; one died of perforated bowel; and one died from an unknown cause.
Conclusion: Although there is a higher mortality rate in HCV-infected renal
allograft recipients, HCV infection is not a contraindication to renal trans-
plantation. Transplantation is the best option for patients with HCV-infected
end-stage renal failure. Adjustment of immunosuppression and careful follow-
up are mandatory in order to detect infection and worsening of liver disease
earlier.
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Background: Tacrolimus is a substrate for cytochrome P450 3A isoenzymes
and P-glycoprotein encoded by MDR1. Polymorphisms in the CYP3A
isoenzymes and MDR1 may play an important role in tacrolimus
pharmacokinetics. We genotyped CYP3A and MDR1 polymorphisms and
examined the association between these polymorphisms and the pharma-
cokinetics of tacrolimus in Chinese renal transplant recipients. Methods: An
abbreviated AUC was calculated using limited blood sampling strategy in 50
Chinese renal transplant recipients. Genotypes were determined using real-
time PCR FRET assays. The frequency and influence of MDR1 (C1236T,
G2677T/A, C3435T), CYP3A4 (A-392G) and CYP3A5 (A6986G)
polymorphisms on the dose-adjusted AUC (ng • hr/mL/mg/kg) and on the dose
requirement (mg/kg/day) was analyzed using the non-parametric Kruskal-Wallis
and the Mann Whitney U test. Results: The tacrolimus dose (mg/kg/day) was
significantly higher in CYP3A5*1/*1 (10% of Chinese patients) or MDR1
2677TT carriers (20%) than in CYP3A5*3/*3 or MDR1 2677GG carriers
[0.13 (0.05–0.18 mg/kg/day) vs 0.048 (0.01–0.09 mg/kg/day), p < 0.000] and
[0.074 (0.05–0.11 mg/kg/day) vs 0.048 (0.03–0.09 mg/kg/day), p = 0.022],
respectively.  The dose-adjusted AUC was significantly lower in
CYP3A5*1/*1 and MDR1 2677TT carriers than in CYP3A5*3/*3 and MDR
2677GG carriers. The other CYP3A and MDR1 polymorphisms were not
associated with significant altered tacrolimus dosage. Conclusion: Renal
transplant recipients carrying the CYP3A5*1/*1 or MDR1 2677TT genotype
required a higher daily tacrolimus dose compared with those with a CYP3A5*3/*3
or MDR1 2677GG genotype to maintain the tacrolimus blood level within the
therapeutic window.
